By Ludwig Burger
FRANKFURT (Reuters) -Roche’s third-quarter gross sales acquired a currency-adjusted 9%, defeating market assumptions, on larger prescriptions of once-monthly haemophilia shot Hemlibra and only in the near past launched eye treatment Vabysmo.
Group gross sales of 15.14 billion Swiss francs ($ 17.46 billion) exceeded an consultants’ settlement quote of 14.9 billion francs, based mostly upon LSEG info.
The Swiss drugmaker declared on Wednesday it anticipates growth in 2024 modified earnings per share within the “high single-digit range”, leaving out the results of cash swings and determination of tax obligation conflicts in 2023.
($ 1 = 0.8671 Swiss francs)
(Reporting by Ludwig Burger, Editing by Rachel More)
